ProBioGen Co-Develops New Freedom™ ExpiCHO-S™ Cell Line Development Kit
Friday, October 28, 2022
ProBioGen and Thermo Fisher Scientific have joined forces once again, building upon the success of the Gibco™ Freedom™ CHO-S Cell Line Development Kit, to introduce an enhanced platform called the Gibco™ Freedom™ ExpiCHO-S™ Cell Line Development Kit. This advanced kit enables users to generate cell lines suitable for clinical development without the need for their own starter cells, vectors, or prior experience in the field. Leveraging ProBioGen's expertise in cell line and process development, the Freedom ExpiCHO-S Kit offers improved performance and capabilities.
The new kit harnesses Thermo Fisher's ExpiCHO-S cell line and a powerful media platform specifically designed for it. It incorporates a novel set of ProBioGen vectors equipped with robust promoters, selection markers, and protective elements to ensure expression stability. Furthermore, ProBioGen has optimized the workflow, resulting in a shortened development time, consistently high titers (ranging from 3 to 5 g/L), and sustained expression stability.
Dr. Volker Sandig, Chief Scientific Officer at ProBioGen, emphasized the importance of establishing a stable and high-performing cell line as the foundation for successful pharmaceutical development. The Gibco Freedom ExpiCHO-S Kit facilitates a seamless transition from transient to stable production, faithfully reproducing previously observed product modifications. The unique vector composition offered by ProBioGen allows for flexibility in developing not only antibodies but also various novel product formats.
The Gibco Freedom ExpiCHO-S Kit is available for purchase through Thermo Fisher Scientific.
For more information about the collaboration between ProBioGen and Thermo Fisher on this new kit, as well as to receive updates from ProBioGen, you can sign up for their newsletter. Subscribers will gain access to content including the "Inside Bioprocessing" podcast episode titled "Optimizing stable clone development to improve biopharmaceutical production." The podcast delves into topics such as plasmid design and expression, expanding desired clones for stable protein production, streamlining the process, and the future of stable clone development.
